Nanoplasmid Replication Origin Switch for Safer High-Yield Vectors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing plasmid vectors face challenges such as promiscuous replication in endogenous bacterial flora, expression of antibiotic resistance markers, and short transgene expression duration, which are not efficiently addressed by current manufacturing methods, leading to safety concerns and reduced efficacy.
Innovation Solution
Utilization of a Pol III-dependent origin of replication to replace Pol I-dependent origins in plasmids, specifically the R6K gamma replication origin, to improve manufacturing yield and quality, and eliminate antibiotic markers, and RNA selectable markers, thereby improving replication and transfection associated toxicity, and enhancing expression and eliminating antibiotic resistance marker gene transfer risk, while maintaining efficient production and expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If Pol I-dependent origin of replication (e.g., pUC, pMB1, ColE1) is used in plasmid vectors, then high copy number and efficient bacterial propagation are achieved, but promiscuous replication in endogenous bacterial flora occurs causing safety concerns
Solution Approach 1:
The patent extracts and removes the Pol I-dependent origin of replication (pUC, pMB1, or ColE1) from the plasmid vector, replacing it with a Pol III-dependent origin (R6K gamma). This extraction eliminates the harmful promiscuous replication capability while maintaining efficient plasmid production through the alternative replication mechanism.
Solution Approach 2:
The patent changes the fundamental parameter of replication dependency from Pol I to Pol III by replacing the origin of replication. This parameter change transforms the replication mechanism to achieve both high copy number and restricted host range, solving the safety issue while maintaining productivity.
2Productivity
If antibiotic resistance markers are included in plasmid vectors for selection, then efficient bacterial transformation selection is achieved, but antibiotic resistance marker expression in human cells and potential gene transfer occurs
Solution Approach 1:
The patent extracts and removes antibiotic resistance markers from the plasmid vector construction. By eliminating these markers, the vector prevents antibiotic resistance expression in human cells and eliminates the risk of antibiotic resistance gene transfer, while maintaining selection capability through alternative methods.
Solution Approach 2:
The patent replaces permanent antibiotic resistance markers with temporary or conditional selection systems that do not confer long-term resistance. This allows efficient selection during transformation while preventing persistent harmful expression in therapeutic applications.
3Ease of manufacture
If conventional plasmid vectors are used for gene therapy, then ease of manufacture is maintained, but transgene expression duration is short due to promoter inactivation
Solution Approach 1:
The patent changes the replication origin parameter from Pol I-dependent to Pol III-dependent, which fundamentally alters plasmid maintenance and expression characteristics. This parameter change extends transgene expression duration by preventing promoter inactivation while maintaining ease of manufacture through established pol III-dependent replication systems.
Data Source
AI summary
A method for improving the replication of a covalently closed circular plasmid is provided. The method includes providing a covalently closed circular plasmid having a Pol I-dependent origin of replication, and an insert including a structured DNA sequence selected from inverted repeat sequences, direct repeat sequences, homopolymeric repeat sequences, eukaryotic origins of replication or eukaryotic promoter enhancer sequences, wherein the structured DNA sequence is located at a distance of less than 1000 bp from the Pol I-dependent origin of replication in the direction of replication. The method also includes modifying the covalently closed circular recombinant molecule such that the Pol I-dependent origin of replication is replaced with a Pol III-dependent origin of replication, whereby the resultant Pol III-dependent origin of replication covalently closed circular plasmid has improved replication. An antibiotic marker free covalently closed circular recombinant DNA molecule is also provided.